Skip to content

house · Committee report

H. Rept. 119-817

TYLER'S LAW

2026-09-14

Committees

Associated legislation

Text

Purpose and Summary

H.R. 2004, Tyler's Law, directs the Secretary of Health and Human Services (HHS) to study the use of fentanyl testing in hospital emergency departments for patients experiencing an overdose. The study shall then inform guidance, issued by the Secretary, on whether hospital emergency departments should implement fentanyl testing as a routine procedure for patients experiencing an overdose.

Background and Need for Legislation

Within the last decade, both nonfatal and fatal overdoses involving fentanyl have increased rapidly.\1\ In 2023 alone, roughly 69 percent of all drug overdose deaths involved synthetic opioids other than methadone.\2\ H.R. 2004, Tyler's Law, is named after Tyler Shamash, a 19-year-old boy who died of fentanyl poisoning in 2018.\3\ While in the emergency room, the standard opioid test administered to Tyler did not test for fentanyl.\4\ --------------------------------------------------------------------------- \1\Ctrs. for Disease Control & Prevention, NCHS Data Brief: No. 522, Drug Overdose Deaths in the United States, 2003-2023 (Dec. 2024), https://www.cdc.gov/nchs/data/databriefs/db522.pdf. \2\Ctrs. for Disease Control & Prevention, Fentanyl, Overdose Prevention (Jun. 2025), https://www.cdc.gov/overdose-prevention/about/ fentanyl.html. \3\Julie Shamash, Stories: Tyler Shamash, Voices from the Opioid Crisis (last accessed Sept. 2026), https:// voicesfromtheopioidcrisis.com/tyler-shamash/. \4\Id. --------------------------------------------------------------------------- Testing for fentanyl as part of a drug screening panel in clinical settings is conducted at the hospital's discretion if there is no testing requirement by the state.\5\ Testing uptake varies by hospitals, for reasons such as the costs of the tests, the time required to receive test results, and lack of standardized clinical guidance.\6\ H.R. 2004 would examine current fentanyl testing practices, associated costs, as well as risks and benefits of testing for fentanyl within hospital emergency departments. These findings would then be utilized to issue guidance for hospital emergency departments to inform appropriate implementation of fentanyl testing as a routine procedure for patients experiencing an overdose. --------------------------------------------------------------------------- \5\Amanda K. Sarata, Cong. Rsch. Serv. (CRS), IN12219, Clinical Fentanyl Testing (2023). \6\Reagan-Udall Foundation for the FDA, Fentanyl Drug Checking and Screening: Roundtable on Clinical Perspectives Summary Report, (last accessed Sept. 2026), https://reaganudall.org/sites/default/files/2022- 06/FTS_Clinician%20Roundtable_Final_Complete%206.30.pdf. ---------------------------------------------------------------------------

Committee Action

On March 26, 2026, the Subcommittee on Health held a hearing on H.R. 2004. The Subcommittee received testimony from: Scott Oulton, President, INTR3PID Solutions LLC K. Fred Gingrich II, DVM, Executive Director, American Association of Bovine Practitioners Dennis Lemma, Sheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America Nabarun Dasgupta, PhD, MPH, Senior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel Hill Yngvild Olsen, MD, MPH, Former Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt Health On June 25, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 2004, without amendment, to the full Committee by a voice vote. On July 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 2004, without amendment, favorably reported to the House by a record vote of 46 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] OVERSIGHT FINDINGS AND RECOMMENDATIONS Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held (a) hearing(s) and made findings that are reflected in this report. NEW BUDGET AUTHORITY, ENTITLEMENT AUTHORITY, AND TAX EXPENDITURES Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 2004 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. FEDERAL MANDATES STATEMENT The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. STATEMENT OF GENERAL PERFORMANCE GOALS AND OBJECTIVES Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to direct the Secretary of HHS to study the use of fentanyl testing in hospital emergency departments to inform guidance on the implementation of fentanyl testing as a routine procedure for patients experiencing an overdose. DUPLICATION OF FEDERAL PROGRAMS Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 2004 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. RELATED COMMITTEE AND SUBCOMMITTEE HEARINGS Pursuant to clause 3(c)(6) of rule XIII, the following related hearing was used to develop or consider H.R. 2004: On February 6, 2025, the Subcommittee on Health held a hearing on H.R. 2004. The title of the hearing was ``Combatting Existing and Emerging Illicit Drug Threats.'' The Subcommittee received testimony from: Sheriff Michael Bouchard, Vice President of Government Affairs, Major County Sheriffs Association; Mr. Raymond Cullen, Family Advocate; Dr. Timothy Westlake, MD, FFSMB, FACEP, Emergency Medicine Physician, ProHealth Care Oconomowoc Memorial Hospital; Ms. Regina LaBelle, JD, Professor and Director, Master of Science in Addiction Policy and Practice, Georgetown University (Minority); and, Dr. Deepa Camenga, MD, MHS, FAAP, Chair, Committee on Substance Use and Prevention, American Academy of Pediatrics (Minority). On March 26, 2026, the Subcommittee on Health held a hearing on H.R. 2004. The title of the hearing was ``Policies to Protect Our Communities From Illicit Drug Threats.'' The Subcommittee received testimony from: Scott Oulton, President, INTR3PID Solutions LLC; K. Fred Gingrich II, DVM, Executive Director, American Association of Bovine Practitioners; Dennis Lemma, Sheriff, Seminole County, Florida, and Former President of the Major County Sheriffs of America; Nabarun Dasgupta, PhD, MPH, Senior Scientist and Gillings Innovation Fellow, University of North Carolina at Chapel Hill; and, Yngvild Olsen, MD, MPH, Former Director of the Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, and National Advisor, Manatt Health. COMMITTEE COST ESTIMATE Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. EARMARK, LIMITED TAX BENEFITS, AND LIMITED TARIFF BENEFITS Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 2004 contains no earmarks, limited tax benefits, or limited tariff benefits. ADVISORY COMMITTEE STATEMENT No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. APPLICABILITY TO LEGISLATIVE BRANCH The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. SECTION-BY-SECTION ANALYSIS OF THE LEGISLATION Section 1. Short title Section 1 provides a short title of ``Tyler's Law''. Section 2. Testing for fentanyl in hospital emergency departments Section 2 directs the Secretary of HHS complete a study regarding the frequency of hospital emergency department testing for fentanyl during an overdose, the cost of testing for fentanyl, the potential benefits and risks with testing for fentanyl, and the ways in which fentanyl testing in hospital emergency departments impacts the patient experience. Following the conclusion of the study, this section directs the Secretary of HHS issue guidance on the whether hospital emergency departments should implement fentanyl testing for patients experiencing an overdose, how hospital emergency departments can improve clinician awareness of which substances can be identified by administered drug tests, and how testing practices could affect the risk of overdose and health outcomes. [all]

Source: https://api.congress.gov/v3/committee-report/119/hrpt/817